MARKET

PRVL

PRVL

Prevail
NASDAQ

Real-time Quotes | Nasdaq Last Sale

14.90
-0.14
-0.93%
Opening 10:50 07/13 EDT
OPEN
15.09
PREV CLOSE
15.04
HIGH
15.14
LOW
14.78
VOLUME
12.02K
TURNOVER
--
52 WEEK HIGH
19.96
52 WEEK LOW
7.41
MARKET CAP
509.61M
P/E (TTM)
-4.7686
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 7 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average PRVL stock price target is 22.00 with a high estimate of 25.00 and a low estimate of 20.00.

EPS

PRVL News

More
Hedge Funds Are Buying Prevail Therapeutics Inc. (PRVL)
The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filings show the funds' and investors' portfolio positions as of
Insider Monkey · 07/04 18:44
Prevail Therapeutics Appoints Kira Schwartz, J.D., as General Counsel
NEW YORK, June 04, 2020 -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with.
GlobeNewswire · 06/04 11:00
The Daily Biotech Pulse: Cumberland's Positive Anti-Bacterial Readout, FDA Nods For Bristol-Myers, Astellas
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 26)
Benzinga · 05/27 11:25
Prevail Therapeutics to Present at The Jefferies Virtual Global Healthcare Conference
NEW YORK, May 26, 2020 -- Prevail Therapeutics Inc. (Nasdaq: PRVL) (“Prevail” or “the Company”), a biotechnology company developing potentially disease-modifying AAV-based gene.
GlobeNewswire · 05/26 20:01
Stocks That Hit 52-Week Highs On Tuesday
On Tuesday, 118 companies set new 52-week highs.
Benzinga · 05/26 14:32
Wedbush Maintains Outperform on Prevail Therapeutics, Raises Price Target to $22
Wedbush maintains Prevail Therapeutics (NASDAQ:PRVL) with a Outperform and raises the price target from $19 to $22.
Benzinga · 05/26 12:00
Prevail Therapeutics to Participate in Fireside Chat at Chardan 4th Annual Genetic Medicines Manufacturing Summit
CEO, CTO to Discuss Company’s Manufacturing and CMC Strategy and Overall Industry Trends NEW YORK, May 21, 2020 -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology.
GlobeNewswire · 05/21 21:46
Prevail Therapeutics Reports First Quarter 2020 Financial Results and Business Highlights
GlobeNewswire · 05/14 12:00

Industry

Biotechnology & Medical Research
+1.01%
Pharmaceuticals & Medical Research
+1.50%

Hot Stocks

Symbol
Price
%Change

About PRVL

Prevail Therapeutics Inc. is a gene therapy company. The Company is developing and commercializing adeno-associated virus (AAV)-based gene therapies for patients with neurodegenerative diseases. It is engaged in applying a precision medicine approach to neurodegeneration by studying its gene therapies in genetically defined patient populations. The Company’s lead program is PR001 for the treatment of Parkinson’s disease with gaucher disease mutation, and neuronopathic gaucher disease. The Company is focused on developing a broad pipeline of gene therapies for a range of neurodegenerative diseases, including PR006 for the treatment of frontotemporal dementia with GRN mutation and PR004 for the treatment of synucleinopathies.
More

Webull offers kinds of Prevail Therapeutics Inc stock information, including NASDAQ:PRVL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PRVL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PRVL stock methods without spending real money on the virtual paper trading platform.